|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N05AE04
|
|
gptkbp:brand
|
Fanapt
|
|
gptkbp:CASNumber
|
133454-47-4
|
|
gptkbp:category
|
second-generation antipsychotic
|
|
gptkbp:contraindication
|
QT prolongation
known hypersensitivity to iloperidone
|
|
gptkbp:developer
|
gptkb:Vanda_Pharmaceuticals
gptkb:Novartis
|
|
gptkbp:drugClass
|
gptkb:antipsychotic_medication
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C24H27FN2O4
|
|
gptkbp:interactsWith
|
CYP2D6 inhibitors
CYP3A4 inhibitors
other QT-prolonging drugs
|
|
gptkbp:IUPACName
|
1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
141319
160855
DB04946
|
|
gptkbp:riskFactor
|
neuroleptic malignant syndrome
tardive dyskinesia
leukopenia
hyperglycemia
QT interval prolongation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
dizziness
weight gain
tachycardia
somnolence
|
|
gptkbp:synonym
|
Fanapt
HP 873
Zomaril
|
|
gptkbp:UNII
|
71IH826FEG
|
|
gptkbp:usedFor
|
treatment of schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:N05AX
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
iloperidone
|